Immunohistochemical Methods for the Study of the Expression of Low-Affinity Monoamine Transporters in the Brain

  • Franck Louis
  • Thomas Couroussé
  • Sophie GautronEmail author
Part of the Neuromethods book series (NM, volume 118)


Immunohistochemical and molecular methods, such as indirect immunofluorescence and in situ hybridization, have proven irreplaceable in providing an accurate vision of the precise localization of transporters as they occur within their native anatomical context in mammalian central nervous system, an essential prerequisite for understanding their function in vivo. Low-affinity monoamine transporters like organic cation transporters (OCTs) and plasma membrane monoamine transporter (PMAT) represent important yet poorly characterized components of aminergic neurotransmission in the brain. Contrarily to the classical high-affinity reuptake transporters, these low-affinity monoamine transporters are not restricted to the presynaptic terminals, but distributed diffusely in cells of numerous brain areas, in particular of aminergic projection regions. In this chapter, we will provide a detailed description of well-established procedures for diaminobenzidine (DAB) immunohistochemistry and immunofluorescence successfully applied to rodent brain. We also detail immunohistochemistry in situ hybridization co-labeling, a valuable approach which couples the sensitive detection of the cells expressing transporter mRNAs in brain sections with the immunohistochemical identification of these cells. We discuss conditions that can improve transporter detection and identify critical methodological steps in these protocols.

Key words

Immunohistochemistry Immunofluorescence Low-affinity monoamine transporters Central nervous system 



We gratefully acknowledge the contribution of several former team members for the development and application of the methods described, in particular Vincent Vialou, Alexandre Bacq, Laure Balasse, and Quentin Perrenoud. Financial support was provided by the Institut National de la Santé et la Recherche Médicale (Inserm) and Fondation de France and fellowships from the French Ministry for Research, the Fondation pour la Recherche Médicale, and the Société Française de Pharmacologie et Thérapeutique.


  1. 1.
    Breidert T, Spitzenberger F, Grundemann D, Schomig E (1998) Catecholamine transport by the organic cation transporter type 1 (OCT1). Br J Pharmacol 125:218–224CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, Volk C et al (1998) Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 54:342–352PubMedGoogle Scholar
  3. 3.
    Grundemann D, Schechinger B, Rappold GA, Schomig E (1998) Molecular, identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci 1:349–351CrossRefPubMedGoogle Scholar
  4. 4.
    Grundemann D, Koster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F et al (1998) Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem 273:30915–30920CrossRefPubMedGoogle Scholar
  5. 5.
    Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E (1999) Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol 56:1–10PubMedGoogle Scholar
  6. 6.
    Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J et al (1998) Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem 273:32776–32786CrossRefPubMedGoogle Scholar
  7. 7.
    Engel K, Zhou M, Wang J (2004) Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem 279:50042–50049CrossRefPubMedGoogle Scholar
  8. 8.
    Engel K, Wang J (2005) Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol Pharmacol 68:1397–1407CrossRefPubMedGoogle Scholar
  9. 9.
    Amphoux A, Vialou V, Drescher E, Bruss M, Mannoury La Cour C, Rochat C et al (2006) Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 50:941–952CrossRefPubMedGoogle Scholar
  10. 10.
    Vialou V, Balasse L, Dumas S, Giros B, Gautron S (2007) Neurochemical characterization of pathways expressing plasma membrane monoamine transporter in the rat brain. Neuroscience 144:616–622CrossRefPubMedGoogle Scholar
  11. 11.
    Vialou V, Amphoux A, Zwart R, Giros B, Gautron S (2004) Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci 24:2846–2851CrossRefPubMedGoogle Scholar
  12. 12.
    Vialou V, Balasse L, Callebert J, Launay JM, Giros B, Gautron S (2008) Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice. J Neurochem 106:1471–1482PubMedGoogle Scholar
  13. 13.
    Cui M, Aras R, Christian WV, Rappold PM, Hatwar M, Panza J et al (2009) The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A 106:8043–8048CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Gasser PJ, Orchinik M, Raju I, Lowry CA (2009) Distribution of organic cation transporter 3, a corticosterone-sensitive monoamine transporter, in the rat brain. J Comp Neurol 512:529–555CrossRefPubMedGoogle Scholar
  15. 15.
    Bacq A, Balasse L, Biala G, Guiard B, Gardier AM, Schinkel A et al (2012) Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response. Mol Psychiatry 17:926–939CrossRefPubMedGoogle Scholar
  16. 16.
    Dahlin A, Xia L, Kong W, Hevner R, Wang J (2007) Expression and immunolocalization of the plasma membrane monoamine transporter in the brain. Neuroscience 146:1193–1211CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Franck Louis
    • 1
    • 2
    • 3
  • Thomas Couroussé
    • 1
    • 2
    • 3
    • 4
  • Sophie Gautron
    • 1
    • 2
    • 3
    Email author
  1. 1.INSERM U1130ParisFrance
  2. 2.CNRS UMR 8246ParisFrance
  3. 3.UPMC Univ Paris 06Sorbonne UniversitésParisFrance
  4. 4.Université Paris Descartes, Ecole Doctorale Médicament Toxicologie Chimie EnvironnementParisFrance

Personalised recommendations